

Hepatitis C Screening, Evaluation and Treatment

Demographics Module

Patient Insurance Type

Patient Birth Year between 1945-1965 OR Patients has previous highrisk factors, including anyblood transfusions prior to1992 or history of intravenousdrug use / HIV infections / long-term hemodialysis / abnormal ALT / born to a Hepatitis C-positive woman

OR

Patient have Hepatitis C

YES

YES

Screening Module

Has the patient been tested for hepatitis C antibody?

YES

NEGATIVE

OR

POSITIVE

YES

HCV RNA Test Result
and
Genotype

NO

Patient should sent to be to have blood drawn for hepatitis C antibody

Patient need not be revisited

Evaluation Module

High Risk Factors

Fibrosis
Cirrhosis Child-Pugh
Extra-hepatic manifestations
Liver transplant
Other similar High Risk Factors

YES

Patient should be referred to specialists.

AND

Is member treatment experienced?

OR

Alcohol Screening,
Laboratory Test Results and
additional Documents


Treatment = Experienced / Naive

if APRI ≥ 1.5 consider the patient
if Fibroscan ≥ 12.5 Pa (14.5,17.5)
if FibroTest/FibroSure score ≥ 0.75

YES

Cirrhosis = Yes

By then the Insurance Plan type, Genotype, Cirrhosis and Treatment Type of the Patient will get determined. Based on these values Treatment Module can display the Recommendations



Treatment Module

Treatment Recommendation

Medicaid:

GT1: Zepatier one tablet daily, +/-weight based ribavirin for 12 to 16 weeks
GT2/5/6: Epclusa one tablet daily for 12 weeks
GT3: Epclusa one tablet daily, +/-weight based ribavirin for 12 weeks
GT4: Zepatier one tablet daily x 12 weeks

Commercial/Medicare:

GT1: Viekira Pak four tablets daily, +/-weight based ribavirin for 12 weeks
GT2/5/6: Epclusa one tablet daily for 12 weeks
GT3: Epclusa one tablet daily, +/-weight based ribavirin for 12 weeks
GT4: Technivie three tablets daily x 12 weeks, plus weight based ribavirin for 12 weeks

Real World Evidence

Based on Genotype, Cirrhosis and Treatment Type from previous selections the Real World Evidence Top 6 Drugs having scored high Efficacy, Safety, and Adherence are displayed